Centessa Pharmaceuticals Announces Pricing of $250,000,000 Public Offering of American Depositary Shares

Group 1 - Centessa Pharmaceuticals plc has announced the pricing of an underwritten public offering of 11,627,907 American Depositary Shares (ADSs) at a price of $21.50 per ADS, with expected gross proceeds of approximately $250 million before deductions [1] - The offering is expected to close on or about November 14, 2025, subject to customary closing conditions, and includes a 30-day option for underwriters to purchase an additional 1,744,186 ADSs [1] - The ADSs are being offered under a registration statement filed with the SEC, which became effective upon filing [3] Group 2 - Jefferies, Leerink Partners, Evercore ISI, and Guggenheim Securities are acting as joint book-running managers for the offering, while Oppenheimer & Co., Truist Securities, and LifeSci Capital are co-lead managers [2] - The final prospectus supplement and accompanying prospectus related to the offering will be filed with the SEC and will be available on the SEC's website [3] Group 3 - Centessa Pharmaceuticals is a clinical-stage pharmaceutical company focused on discovering and developing transformative medicines, particularly in the area of orexin receptor 2 (OX2R) agonist program for treating excessive daytime sleepiness and other neurological disorders [5]